Not sure what biotech companies you are comparing with. However, there are some points here to remember. First, you say other biotechs have higher trading values compared to Oncosil. I would agree. But they are generally drug companies and potential takeover targets by Big Pharma.
Compare that to Oncosil:- Not a drug company but instead a medical device company. And medical devices have not been viewed well by the market. Second issue there doesn’t appear to be any company wanting to takeover Oncosil. In fact the opposite is happening. No interest by the market virtually at all. So, when you take away the prospect of Big Pharma making a play, you have the result we have. Share price going nowhere fast.
Third, you have another big problem here. There are virtually no sales. Every single quarter. It’s great to say we have a terrific product but if you can’t get public reimbursement easily because of no RCT’s then you are in a catch 22.
So, this is where we are at. More importantly, it’s were the market thinks we are at.
OSL Price at posting:
0.9¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)